Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > COLUMN
COLUMN
-
Customer Engagement in the COVID-Endemic New Normal
June 17, 2022
-
Tapping into One’s Ikigai by Working from Home
May 27, 2022
-
The Road to Success Is Paved with the Stepping-Stones of Disappointment
April 22, 2022
-
Five Ways to Get Your New Hire on the Same Page
March 31, 2022
-
4 Things You Can Do to Overcome Zoom Overload
November 26, 2021
-
What Does a Great Boss Look Like?
October 29, 2021
-
What Is the Price of a Work-Life Balance?
September 24, 2021
-
Obituary: P. Reed Maurer
September 14, 2021
-
Digital and Cultural Transformation in Japanese Pharmaceuticals
August 13, 2021
-
How Manufacturers Can Optimize Wholesaler Relationships and Leverage Wholesalers to Support Business Strategy
July 13, 2021
-
Does Your Company Want to Increase Its Diversity?
July 5, 2021
-
5 Lessons in 5 Years from Rocking the Bag
June 17, 2021
-
Pricing Reform in Japan - How Manufacturers Can Ensure Fair Compensation for Value and Innovation
May 28, 2021
-
Set the Stage for an Exceptional Customer Experience
May 21, 2021
-
Pricing Reform in Japan: How Must Life Science Companies Evolve?
April 23, 2021
-
Do You Attract or Repel Winning Candidates?
April 16, 2021
-
The Future of Customer Engagement in Japan’s Life Science Industry: One Year Post-COVID
March 19, 2021
-
Bring Your A-Game to Your Next Video Call
March 11, 2021
-
What Personal Biases Influence Your Hires?
February 19, 2021
-
Is Your Company Culture Being a Victim of COVID-19?
January 8, 2021
ページ
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…